|
Exchange: |
OTC Bulletin Board |
Security
Type: |
Common |
Shares
Out: |
27,801,000 |
Market
Cap: |
131.36(K) |
Last
Volume: |
143,905 |
Avg
Vol: |
143,507 |
52
Week Range: |
$0.0035 - $0.01 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drugs - Generic |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Lotus Pharmaceuticals is a holding company with its principal place of business in China. Co. operates, controls and beneficially owns the pharmaceutical business of Beijing Liang Fang Pharmaceutical Co., Ltd. and Beijing En Ze Jia Shi Pharmaceutical Co., Ltd. (collectively, Lotus East). Lotus East produces crude medicine and drugs in forms of tablets, capsules, granules, eye-drops, and freeze-dried powder injection. Lotus East manufactures four branded drugs which includes: Valsartan; Brimonidine Tartrate Eye Drops; Levofloxacin Lactate for Injection; and Nicergoline for Injection. As of Dec 31 2010, Lotus East owned and operated 10 drug stores throughout different districts of Beijing.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|